Comorbidities• CKD (OR: 3.14; 95% CI: 2.49–3.96; P < .001)• Ascites (OR: 1.60; 95% CI: 1.27–2.00; P < .001)• Obesity (OR: 1.48; 95% CI: 1.20–1.86; P = .001)AKI severity: AKI stages 2/3 (OR: 9.37; 95% CI: 7.02–12.50; p < .001)AKI setting: Community-acquired AKI (OR: 1.63; 95% CI: 1.25–2.14; P < .001)Lower serum albumin at time of AKI (OR: 1.37; 95% CI: 1.07–1.75; P = .013)Lower MAP at time of AKI (per 1 mmHg decrease, OR: 1.01; 95% CI: 1.00–1.03; P < .001). This evidence concerns the gene ALB and chronic kidney disease.